A Multicenter, Single-Arm, Exploratory Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer in Patients Who Are Intolerant to Chemotherapy or Have Failed Chemotherapy
Latest Information Update: 31 Mar 2026
At a glance
- Drugs Becotatug vedotin (Primary) ; Pucotenlimab
- Indications Penile cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 31 Mar 2026 New trial record